<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="http://www.fda.gov/oc/datacouncil/stylesheets/spl/spl.xsl" type="text/xsl"?><document xmlns="urn:hl7-org:v3" xmlns:voc="http://www.hl7.org/v3/voc" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 http://www.fda.gov/oc/datacouncil/schemas/spl/spl.xsd">
<id root="63656F64-E240-4855-8DF9-CA1655863735" />
<code code="34391-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="HUMAN PRESCRIPTION DRUG LABELING" />
<title mediaType="text/x-hl7-title+xml"><content styleCode="bold">Targretin<sup>&#174;</sup> (bexarotene)
            capsules, 75 mg</content></title>
<effectiveTime value="20060328" />
<setId root="63656F64-E240-4855-8DF9-CA1655863735" />
<versionNumber value="1" />
<author>
<time />
<assignedEntity>
<representedOrganization>
<name>Cardinal Health</name>
</representedOrganization>
</assignedEntity>
</author>
<component>
<structuredBody>
<component>
<section>
<id root="14A842B6-97AC-88F1-FCCE-165E34DC5FF3" />
<effectiveTime value="20060328" />
<subject>
<manufacturedProduct>
<manufacturedMedicine>
<code code="64365-502" codeSystem="2.16.840.1.113883.6.69" />
<name>Targretin</name>
<formCode code="C25158" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE" />
<activeIngredient>
<quantity>
<numerator unit="mg" value="75">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="75" />
</numerator>
<denominator value="1">
<translation code="C48480" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE" value="1" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="A61RXM4375" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>bexarotene</name>
<activeMoiety>
<activeMoiety>
<code code="A61RXM4375" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>bexarotene</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<asEntityWithGeneric>
<genericMedicine>
<name>bexarotene</name>
</genericMedicine>
</asEntityWithGeneric>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>polyethylene glycol 400</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>polysorbate 20</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>povidone</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>butylated hydroxyanisole</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>gelatin</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>sorbitol special-glycerin blend</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>titanium dioxide</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<asContent>
<quantity>
<numerator value="100">
<translation code="C48480" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE" value="100" />
</numerator>
<denominator value="1">
<translation value="1" />
</denominator>
</quantity>
<containerPackagedMedicine>
<code code="64365-502-01" codeSystem="2.16.840.1.113883.6.69" />
<formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE" />
</containerPackagedMedicine>
</asContent>
</manufacturedMedicine>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255" />
<value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE"><originalText>OFF-WHITE</originalText></value>
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255" />
<value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE"><originalText>CAPSULE</originalText></value>
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSYMBOL" codeSystem="2.16.840.1.113883.1.11.19255" />
<value value="false" xsi:type="BL" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLCOATING" codeSystem="2.16.840.1.113883.1.11.19255" />
<value value="false" xsi:type="BL" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255" />
<value unit="mm" value="19" xsi:type="PQ" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255" />
<value value="1" xsi:type="INT" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255" />
<value xsi:type="ST">Targretin</value>
</characteristic>
</subjectOf>
<consumedIn>
<substanceAdministration>
<routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL" />
</substanceAdministration>
</consumedIn>
</manufacturedProduct>
</subject>
</section>
</component>
<component>
<section ID="SF8AE95F1-B0D9-4661-8875-2E0B6F46821B">
<id root="E7E40B1E-8F1B-C4FE-1768-AFD40B7AE8B8" />
<code code="34066-1" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="BOXED WARNING" />
<text><content styleCode="bold">Targretin<sup>&#174;</sup> capsules are a
                            member of the retinoid class of drugs that is associated with birth
                            defects in humans. Targretin<sup>&#174;</sup> capsules also caused
                            birth defects when administered orally to pregnant rats.
                                Targretin<sup>&#174;</sup> capsules must not be administered to
                            a pregnant woman. See <linkHtml href="#SF5DD9F0A-CDCF-4502-B2A4-7EDA828D92E9">CONTRAINDICATIONS</linkHtml>.</content></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="SB3B04C2C-5018-43B9-B337-17B82E3BDCE2">
<id root="D44F1FC2-83FA-DA5A-9FE5-4E82D9C527DE" />
<code code="34089-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="DESCRIPTION" />
<title mediaType="text/x-hl7-title+xml">DESCRIPTION</title>
<text><paragraph>Targretin<sup>&#174;</sup> (bexarotene) is a member of a
                            subclass of retinoids that selectively activate retinoid X receptors
                            (RXRs). These retinoid receptors have biologic activity distinct from
                            that of retinoic acid receptors (RARs). Each soft gelatin capsule for
                            oral administration contains 75 mg of bexarotene.</paragraph><paragraph>The chemical name is
                            4-[1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl) ethenyl]
                            benzoic acid, and the structural formula is as follows:</paragraph><paragraph><renderMultiMedia referencedObject="MM10" /></paragraph><paragraph>Bexarotene is an off-white to white powder with a molecular
                            weight of 348.48 and a molecular formula of
                                C<sub>24</sub>H<sub>28</sub>O<sub>2</sub>. It is insoluble in water
                            and slightly soluble in vegetable oils and ethanol, USP.</paragraph><paragraph>Each Targretin<sup>&#174;</sup> (bexarotene) capsule also
                            contains the following inactive ingredients: polyethylene glycol 400,
                            NF, polysorbate 20, NF, povidone, USP, and butylated hydroxyanisole, NF.
                            The capsule shell contains gelatin, NF, sorbitol special-glycerin blend,
                            and titanium dioxide, USP.</paragraph></text>
<effectiveTime value="20060328" />
<component>
<observationMedia ID="MM10">
<value mediaType="image/jpg" xsi:type="ED"><reference value="targretin-capsule-figure-1.jpg" /></value>
</observationMedia>
</component>
</section>
</component>
<component>
<section ID="S5D44516D-461D-4F16-BD5C-9CB86E458110">
<id root="6B26E39A-8AEF-4DC2-CBBB-60172BF1ABBD" />
<code code="34090-1" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="CLINICAL PHARMACOLOGY" />
<title mediaType="text/x-hl7-title+xml">CLINICAL PHARMACOLOGY</title>
<effectiveTime value="20060328" />
<component>
<section ID="S88112C30-D434-4BBF-8394-420CBC09A9CA">
<id root="CBF56099-CAD7-5FA2-B5E2-05FDE7BC7B53" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Mechanism of Action</title>
<text><paragraph>Bexarotene selectively binds and activates retinoid X
                                    receptor subtypes (RXR&#945;, RXR&#946;, RXR&#947;).
                                    RXRs can form heterodimers with various receptor partners such
                                    as retinoic acid receptors (RARs), vitamin D receptor, thyroid
                                    receptor, and peroxisome proliferator activator receptors
                                    (PPARs). Once activated, these receptors function as
                                    transcription factors that regulate the expression of genes that
                                    control cellular differentiation and proliferation. Bexarotene
                                    inhibits the growth <content styleCode="italics">in
                                    vitro</content> of some tumor cell lines of hematopoietic and
                                    squamous cell origin. It also induces tumor regression <content styleCode="italics">in vivo </content>in some animal models.
                                    The exact mechanism of action of bexarotene in the treatment of
                                    cutaneous T-cell lymphoma (CTCL) is unknown.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="S8C8E17FC-02ED-4E86-B802-B372252E5FD9">
<id root="5BD111AE-4A70-B3DF-E2EF-783BDA1105DA" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Pharmacokinetics</title>
<effectiveTime value="20060328" />
<component>
<section ID="S3AF57D84-C015-41B3-B338-725B089824E9">
<id root="56B9AD74-D482-11AC-2B3B-5297C28B9A5D" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">General</title>
<text><paragraph>After oral administration of
                                                Targretin<sup>&#174;</sup> capsules, bexarotene
                                            is absorbed with a T<sub>max</sub> of about two hours.
                                            Terminal half-life of bexarotene is about seven hours.
                                            Studies in patients with advanced malignancies show
                                            approximate single dose linearity within the therapeutic
                                            range and low accumulation with multiple doses. Plasma
                                            bexarotene AUC and C<sub>max</sub> values resulting from
                                            a 75 to 300 mg dose were 35% and 48% higher,
                                            respectively, after a fat-containing meal than after a
                                            glucose solution (see <content styleCode="bold"><linkHtml href="#S3C0458AE-1228-460A-BB59-BCBF1EAAB56C">PRECAUTIONS: Drug-Food Interaction</linkHtml></content> and <content styleCode="bold"><linkHtml href="#SCC8B9605-DEA6-4590-A5E4-846B77ACFFB7">DOSAGE AND ADMINISTRATION</linkHtml></content>). Bexarotene is highly bound (&gt;99%) to
                                            plasma proteins. The plasma proteins to which bexarotene                                binds have not been elucidated, and the ability of
                                            bexarotene to displace drugs bound to plasma proteins
                                            and the ability of drugs to displace bexarotene binding
                                            have not been studied (see <content styleCode="bold"><linkHtml href="#SCF139D4B-B288-4E1D-8D40-DCA3EF4CCEF7">PRECAUTIONS: Protein
                                            Binding</linkHtml>)</content>. The uptake of bexarotene
                                            by organs or tissues has not been evaluated.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="S222D8E7E-94B2-42F9-A306-D8CAFE39F226">
<id root="DCC28888-085E-4D22-9A0B-78FED3254955" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Metabolism</title>
<text><paragraph>Four bexarotene metabolites have been identified
                                            in plasma: 6- and 7-hydroxy-bexarotene and 6- and
                                            7-oxo-bexarotene. <content styleCode="italics">In
                                            vitro</content> studies suggest that cytochrome P450 3A4
                                            is the major cytochrome P450 responsible for formation
                                            of the oxidative metabolites and that the oxidative
                                            metabolites may be glucuronidated. The oxidative
                                            metabolites are active in <content styleCode="italics">in vitro</content> assays of retinoid receptor
                                            activation, but the relative contribution of the parent
                                            and any metabolites to the efficacy and safety of
                                                Targretin<sup>&#174;</sup> capsules is
                                        unknown.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="S17ACB519-FE8A-4FB2-86F8-8741DA4A849C">
<id root="A5110F6C-3D53-31E7-ED0F-8BD5ADA6EB66" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Elimination</title>
<text><paragraph>The renal elimination of bexarotene and its
                                            metabolites was examined in patients with Type 2
                                            diabetes mellitus. Neither bexarotene nor its
                                            metabolites were excreted in urine in appreciable
                                            amounts. Bexarotene is thought to be eliminated
                                            primarily through the hepatobiliary system.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="S7B34727D-A5F1-46F4-A8FE-6E3F1FBACF57">
<id root="19EE8628-F3D9-D0F2-4BF5-AD2D5904551F" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Special Populations</title>
<text><paragraph>Elderly: Bexarotene C<sub>max</sub> and AUC were
                                            similar in advanced cancer patients &lt;60 years old
                                            and in patients &gt;60 years old, including a subset
                                            of patients &gt;70 years old.</paragraph><paragraph>Pediatric: Studies to evaluate bexarotene
                                            pharmacokinetics in the pediatric population have not
                                            been conducted (see <content styleCode="bold"><linkHtml href="#S20A734D5-751B-4813-923C-16B2F54AF285">PRECAUTIONS: Pediatric Use</linkHtml></content>).</paragraph><paragraph>Gender: The pharmacokinetics of bexarotene were
                                            similar in male and female patients with advanced
                                            cancer.</paragraph><paragraph>Ethnic Origin: The effect of ethnic origin on
                                            bexarotene pharmacokinetics is unknown.</paragraph><paragraph>Renal Insufficiency: No formal studies have been
                                            conducted with Targretin<sup>&#174;</sup> capsules
                                            in patients with renal insufficiency. Urinary
                                            elimination of bexarotene and its known metabolites is a
                                            minor excretory pathway (&lt;1% of administered
                                            dose), but because renal insufficiency can result in
                                            significant protein binding changes, pharmacokinetics                may be altered in patients with renal insufficiency (see<content styleCode="bold"><linkHtml href="#S45052A81-EFD6-4CCB-A386-C9B6DE09ECF1">PRECAUTIONS: Renal Insufficiency</linkHtml></content>).</paragraph><paragraph>Hepatic Insufficiency: No specific studies have
                                            been conducted with Targretin<sup>&#174;</sup>
                                            capsules in patients with hepatic insufficiency. Because
                                            less than 1% of the dose is excreted in the urine
                                            unchanged and there is <content styleCode="italics">in
                                                vitro </content>evidence of extensive hepatic
                                            contribution to bexarotene elimination, hepatic
                                            impairment would be expected to lead to greatly
                                            decreased clearance (see <content styleCode="bold"><linkHtml href="#S71367481-441A-4366-8A99-48DD8B4867A5">WARNINGS: Hepatic insufficiency</linkHtml></content>).</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="SB730B795-CAB5-4286-B703-9FE84B96B8E1">
<id root="874317E7-FFC4-FD4E-C146-9DA8D011B387" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Drug-Drug Interactions</title>
<text><paragraph>No specific studies to evaluate drug interactions
                                            with bexarotene have been conducted. Bexarotene
                                            oxidative metabolites appear to be formed by cytochrome
                                            P450 3A4.</paragraph><paragraph>Because bexarotene is metabolized by cytochrome
                                            P450 3A4, ketoconazole, itraconazole, erythromycin,
                                            gemfibrozil, grapefruit juice, and other inhibitors of
                                            cytochrome P450 3A4 would be expected to lead to an
                                            increase in plasma bexarotene concentrations.
                                            Furthermore, rifampin, phenytoin, phenobarbital and
                                            other inducers of cytochrome P450 3A4 may cause a
                                            reduction in plasma bexarotene concentrations.</paragraph><paragraph>Concomitant administration of
                                                Targretin<sup>&#174;</sup> capsules and
                                            gemfibrozil resulted in substantial increases in plasma
                                            concentrations of bexarotene, probably at least
                                            partially related to cytochrome P450 3A4 inhibition by
                                            gemfibrozil. Under similar conditions, bexarotene                   concentrations were not affected by concomitant
                                            atorvastatin administration. Concomitant administration
                                            of gemfibrozil with Targretin<sup>&#174;</sup>
                                            capsules is not recommended (see <content styleCode="bold"><linkHtml href="#SDD2BA3C4-2FCE-4972-A2A1-5E24C2A9748F">PRECAUTIONS: Drug-Drug Interactions</linkHtml></content>).</paragraph><paragraph>Based on interim data, concomitant administration
                                            of Targretin<sup>&#174;</sup> capsules and tamoxifen
                                            resulted in approximately a 35% decrease in plasma
                                            concentrations of tamoxifen, possibly through an
                                            induction of cytochrome P450 3A4. Based on this known
                                            interaction, bexarotene may theoretically increase the
                                            rate of metabolism and reduce plasma concentrations of
                                            other substrates metabolized by cytochrome P450 3A4,
                                            including oral or other systemic hormonal contraceptives
                                            (see <content styleCode="bold"><linkHtml href="#SF40ACF39-8E2A-4199-B3A7-F9B6A7BAA242">CONTRAINDICATIONS: Pregnancy: Category X</linkHtml></content>
                                            and <content styleCode="bold"><linkHtml href="#SDD2BA3C4-2FCE-4972-A2A1-5E24C2A9748F">PRECAUTIONS: Drug-Drug
                                        Interactions</linkHtml></content>).</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
</section>
</component>
<component>
<section ID="SAA08C398-5257-4FD2-9E14-FEBC20FFD68F">
<id root="97DF268E-6CE5-8375-A620-8D80A47D3487" />
<code code="34092-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="CLINICAL STUDIES" />
<title mediaType="text/x-hl7-title+xml">Clinical Studies</title>
<text><paragraph>Targretin<sup>&#174;</sup> capsules were evaluated in
                                    152 patients with advanced and early stage cutaneous T-cell
                                    lymphoma (CTCL) in two multicenter, open-label,
                                    historically-controlled clinical studies conducted in the U.S.,
                                    Canada, Europe, and Australia.</paragraph><paragraph>The advanced disease patients had disease refractory to
                                    at least one prior systemic therapy (median of two, range one to
                                    six prior systemic therapies) and had been treated with a median
                                    of five (range 1 to 11) prior systemic, irradiation, and/or
                                    topical therapies. Early disease patients were intolerant to,
                                    had disease that was refractory to, or had reached a response
                                    plateau of six months on, at least two prior therapies. The
                                    patients entered had been treated with a median of 3.5 (range 2
                                    to 12) therapies (systemic, irradiation, and/or topical).</paragraph><paragraph>The two clinical studies enrolled a total of 152                                patients, 102 of whom had disease refractory to at least one
                                    prior systemic therapy, 90 with advanced disease and 12 with
                                    early disease. This is the patient population for whom
                                        Targretin<sup>&#174;</sup> capsules are indicated.</paragraph><paragraph>Patients were initially treated with a starting dose of
                                    650 mg/m<sup>2</sup>/day with a subsequent reduction of startingdose to 500 mg/m<sup>2</sup>/day. Neither of these starting
                                    doses was tolerated, and the starting dose was then reduced to
                                    300 mg/m<sup>2</sup>/day. If, however, a patient on 300
                                        mg/m<sup>2</sup>/day of Targretin<sup>&#174;</sup>
                                    capsules showed no response after eight or more weeks of
                                    therapy, the dose could be increased to 400
                                    mg/m<sup>2</sup>/day.</paragraph><paragraph>Tumor response was assessed in both studies by
                                    observation of up to five baseline-defined index lesions using a
                                    Composite Assessment of Index Lesion Disease Severity (CA). This
                                    endpoint was based on a summation of the grades, for all index
                                    lesions, of erythema, scaling, plaque elevation,
                                    hypopigmentation or hyperpigmentation, and area of involvement.
                                    Also considered in response assessment was the presence or
                                    absence of cutaneous tumors and extracutaneous disease
                                    manifestations.</paragraph><paragraph>All tumor responses required confirmation over at least
                                    two assessments separated by at least four weeks. A partial
                                    response was defined as an improvement of at least 50% in the
                                    index lesions without worsening, or development of new cutaneous
                                    tumors or non-cutaneous manifestations. A complete clinical
                                    response required complete disappearance of all manifestations
                                    of disease, but did not require confirmation by biopsy.</paragraph><paragraph>At the initial dose of 300 mg/m<sup>2</sup>/day, 1/62
                                    (1.6%) of patients had a complete clinical tumor response and
                                    19/62 (30%) of patients had a partial tumor response. The rate
                                    of relapse (25% increase in CA or worsening of other aspects of
                                    disease) in the 20 patients who had a tumor response was 6/20
                                    (30%) over a median duration of observation of 21 weeks, and the
                                    median duration of tumor response had not been reached.
                                    Responses were seen as early as 4 weeks and new responses
                                    continued to be seen at later visits.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
</section>
</component>
<component>
<section ID="S080DFBA9-0974-49E0-9437-113DB8A92029">
<id root="F4C47AAB-BC77-8D01-71E3-7C5C6F7F09B1" />
<code code="34067-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="INDICATIONS &amp; USAGE" />
<title mediaType="text/x-hl7-title+xml">INDICATIONS AND USAGE</title>
<text><paragraph>Targretin<sup>&#174;</sup> (bexarotene) capsules are
                            indicated for the treatment of cutaneous manifestations of cutaneous
                            T-cell lymphoma in patients who are refractory to at least one prior
                            systemic therapy.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="SF5DD9F0A-CDCF-4502-B2A4-7EDA828D92E9">
<id root="2B3A4B19-85FC-1D94-719D-C468E3E72FCC" />
<code code="34070-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="CONTRAINDICATIONS" />
<title mediaType="text/x-hl7-title+xml">CONTRAINDICATIONS</title>
<text><paragraph>Targretin<sup>&#174;</sup> capsules are contraindicated in
                            patients with a known hypersensitivity to bexarotene or other components
                            of the product.</paragraph></text>
<effectiveTime value="20060328" />
<component>
<section ID="SF40ACF39-8E2A-4199-B3A7-F9B6A7BAA242">
<id root="58B43029-0B67-CD23-3CDC-27B126B599A6" />
<code code="42228-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="PREGNANCY" />
<title mediaType="text/x-hl7-title+xml">Pregnancy: Category X</title>
<text><paragraph>Targretin<sup>&#174;</sup> (bexarotene) capsules may
                                    cause fetal harm when administered to a pregnant woman.
                                        Targretin<sup>&#174;</sup> capsules must not be given to
                                    a pregnant woman or a woman who intends to become pregnant. If a
                                    woman becomes pregnant while taking
                                    Targretin<sup>&#174;</sup> capsules,
                                        Targretin<sup>&#174;</sup> capsules must be stopped
                                    immediately and the woman given appropriate counseling.</paragraph><paragraph>Bexarotene caused malformations when administered orally
                                    to pregnant rats during days 7-17 of gestation. Developmental
                                    abnormalities included incomplete ossification at 4 mg/kg/day
                                    and cleft palate, depressed eye bulge/microphthalmia, and small
                                    ears at 16 mg/kg/day. The plasma AUC of bexarotene in rats at 4
                                    mg/kg/day is approximately one third the AUC in humans at the
                                    recommended daily dose. At doses greater than 10 mg/kg/day,
                                    bexarotene caused developmental mortality. The no effect dose
                                    for fetal effects in rats was 1 mg/kg/day (producing an AUC
                                    approximately one sixth of the AUC at the recommended human
                                    daily dose).</paragraph><paragraph>Women of child-bearing potential should be advised to
                                    avoid becoming pregnant when Targretin<sup>&#174;</sup>
                                    capsules are used. The possibility that a woman of child-bearing
                                    potential is pregnant at the time therapy is instituted should
                                    be considered. A negative pregnancy test (e.g., serum beta-human
                                    chorionic gonadotropin, beta-HCG) with a sensitivity of at least                           50 mlU/L should be obtained within one week prior to
                                        Targretin<sup>&#174;</sup> capsules therapy, and the
                                    pregnancy test must be repeated at monthly intervals while the
                                    patient remains on Targretin<sup>&#174;</sup> capsules.
                                    Effective contraception must be used for one month prior to the
                                    initiation of therapy, during therapy and for at least one month
                                    following discontinuation of therapy; it is recommended that two
                                    reliable forms of contraception be used simultaneously unless
                                    abstinence is the chosen method. Bexarotene can potentially
                                    induce metabolic enzymes and thereby theoretically reduce the
                                    plasma concentrations of oral or other systemic hormonal
                                    contraceptives (see <content styleCode="bold"><linkHtml href="#SB730B795-CAB5-4286-B703-9FE84B96B8E1">CLINICAL
                                        PHARMACOLOGY: Drug-Drug Interactions</linkHtml></content> and<content styleCode="bold"><linkHtml href="#SDD2BA3C4-2FCE-4972-A2A1-5E24C2A9748F">PRECAUTIONS: Drug-Drug Interactions</linkHtml></content>). Thus, if
                                    treatment with Targretin<sup>&#174;</sup> capsules is
                                    intended in a woman with child-bearing potential, it is strongly
                                    recommended that one of the two reliable forms of contraception
                                    should be non-hormonal. Male patients with sexual partners who
                                    are pregnant, possibly pregnant, or who could become pregnant
                                    must use condoms during sexual intercourse while taking
                                        Targretin<sup>&#174;</sup> capsules and for at least one
                                    month after the last dose of drug.
                                    Targretin<sup>&#174;</sup> capsules therapy should be
                                    initiated on the second or third day of a normal menstrual
                                    period. No more than a one month supply of
                                        Targretin<sup>&#174;</sup> capsules should be given to
                                    the patient so that the results of pregnancy testing can be
                                    assessed and counseling regarding avoidance of pregnancy and
                                    birth defects can be reinforced.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
</section>
</component>
<component>
<section ID="S822CAF9C-B0DD-4B8D-BBFB-D297A51E3A24">
<id root="F43E7C6D-266F-F926-011B-4A4295916112" />
<code code="34071-1" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="WARNINGS" />
<title mediaType="text/x-hl7-title+xml">WARNINGS</title>
<effectiveTime value="20060328" />
<component>
<section ID="SB9C2DFAD-C326-42BC-B032-9D6D13FC5FC3">
<id root="1CDBDCE5-87B3-752A-08A2-CE7AECD17D4B" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<text><paragraph><content styleCode="italics">Lipid
                                    abnormalities:</content> Targretin<sup>&#174;</sup> capsules                      induce major lipid abnormalities in most patients. These must be
                                    monitored and treated during long-term therapy. About 70% of
                                    patients with CTCL who received an initial dose of&#8805;300 mg/m<sup>2</sup>/day of
                                    Targretin<sup>&#174;</sup> capsules had fasting triglyceride
                                    levels greater than 2.5 times the upper limit of normal. About
                                    55% had values over 800 mg/dL with a median of about 1200 mg/dL
                                    in those patients. Cholesterol elevations above 300 mg/dL
                                    occurred in approximately 60% and 75% of patients with CTCL who
                                    received an initial dose of 300 mg/m<sup>2</sup>/day or greater
                                    than 300 mg/m<sup>2</sup>/day, respectively. Decreases in high
                                    density lipoprotein (HDL) cholesterol to less than 25 mg/dL were
                                    seen in about 55% and 90% of patients receiving an initial dose
                                    of 300 mg/m<sup>2</sup>/day or greater than 300
                                    mg/m<sup>2</sup>/day, respectively, of
                                    Targretin<sup>&#174;</sup> capsules. The effects on
                                    triglycerides, HDL cholesterol, and total cholesterol were
                                    reversible with cessation of therapy, and could generally be
                                    mitigated by dose reduction or concomitant antilipemic therapy.</paragraph><paragraph>Fasting blood lipid determinations should be performed
                                    before Targretin<sup>&#174;</sup> capsules therapy is
                                    initiated and weekly until the lipid response to
                                        Targretin<sup>&#174;</sup> capsules is established,
                                    which usually occurs within two to four weeks, and at eight week
                                    intervals thereafter. Fasting triglycerides should be normal or
                                    normalized with appropriate intervention prior to initiating
                                        Targretin<sup>&#174;</sup> capsules therapy. Attempts
                                    should be made to maintain triglyceride levels below 400 mg/dL
                                    to reduce the risk of clinical sequelae (see <content styleCode="bold"><linkHtml href="#SD30B7913-6B24-4191-9D4E-362C1528E958">WARNINGS: Pancreatitis</linkHtml></content>). If fasting triglycerides are elevated or become
                                    elevated during treatment, antilipemic therapy should be
                                    instituted, and if necessary, the dose of
                                        Targretin<sup>&#174;</sup> capsules reduced or
                                    suspended. In the 300 mg/m<sup>2</sup>/day initial dose group,
                                    60% of patients were given lipid lowering drugs. Atorvastatin
                                    was used in 48% (73/152) of patients with CTCL. Because of a
                                    potential drug-drug interaction (see <content styleCode="bold"><linkHtml href="#SDD2BA3C4-2FCE-4972-A2A1-5E24C2A9748F">PRECAUTIONS:
                                        Drug-Drug Interactions</linkHtml></content>), gemfibrozil is not
                                    recommended for use with Targretin<sup>&#174;</sup>
                                    capsules.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="SD30B7913-6B24-4191-9D4E-362C1528E958">
<id root="D5E1E704-9502-E31D-1B19-37F785FEB875" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<text><paragraph><content styleCode="italics">Pancreatitis:</content>
                                    Acute pancreatitis has been reported in four patients with CTCL
                                    and in six patients with non-CTCL cancers treated with
                                        Targretin<sup>&#174;</sup> capsules; the cases were
                                    associated with marked elevations of fasting serum
                                    triglycerides, the lowest being 770 mg/dL in one patient. One
                                    patient with advanced non-CTCL cancer died of pancreatitis.
                                    Patients with CTCL who have risk factors for pancreatitis (e.g.,
                                    prior pancreatitis, uncontrolled hyperlipidemia, excessive
                                    alcohol consumption, uncontrolled diabetes mellitus, biliary
                                    tract disease, and medications known to increase triglyceride
                                    levels or to be associated with pancreatic toxicity) should
                                    generally not be treated with Targretin<sup>&#174;</sup>
                                    capsules (see <content styleCode="bold"><linkHtml href="#SB9C2DFAD-C326-42BC-B032-9D6D13FC5FC3">WARNINGS: Lipids abnormalities</linkHtml></content> and <content styleCode="bold"><linkHtml href="#S523E0640-9C6B-45EE-A284-7B403BC5AE4B">PRECAUTIONS:
                                        Laboratory Tests</linkHtml></content>).</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="SE98A15C3-2C02-4A58-B0AC-227AB81F0F8F">
<id root="5ECFD185-0FBA-3F6B-BB7C-975AA321407A" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<text><paragraph><content styleCode="italics">Liver function test
                                        abnormalities:</content> For patients with CTCL receiving an
                                    initial dose of 300 mg/m<sup>2</sup>/day of
                                        Targretin<sup>&#174;</sup> capsules, elevations in liver
                                    function tests (LFTs) have been observed in 5% (SGOT/AST), 2%
                                    (SGPT/ALT), and 0% (bilirubin). In contrast, with an initial
                                    dose greater than 300 mg/m<sup>2</sup>/day of
                                        Targretin<sup>&#174;</sup> capsules, the incidence of
                                    LFT elevations was higher at 7% (SGOT/AST), 9% (SGPT/ALT), and
                                    6% (bilirubin). Two patients developed cholestasis, including
                                    one patient who died of liver failure. In clinical trials,
                                    elevation of LFTs resolved within one month in 80% of patients
                                    following a decrease in dose or discontinuation of therapy.          Baseline LFTs should be obtained, and LFTs should be carefully
                                    monitored after one, two and four weeks of treatment initiation,
                                    and if stable, at least every eight weeks thereafter during
                                    treatment. Consideration should be given to a suspension or
                                    discontinuation of Targretin<sup>&#174;</sup> capsules if
                                    test results reach greater than three times the upper limit of
                                    normal values for SGOT/AST, SGPT/ALT, or bilirubin.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="S71367481-441A-4366-8A99-48DD8B4867A5">
<id root="AADBDE8D-F0F5-4F5D-2E23-B3BE0BEB7A06" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<text><paragraph><content styleCode="italics">Hepatic
                                    insufficiency:</content> No specific studies have been conducted
                                    with Targretin<sup>&#174;</sup> capsules in patients with
                                    hepatic insufficiency. Because less than 1% of the dose is
                                    excreted in the urine unchanged and there is <content styleCode="italics">in vitro</content> evidence of extensive
                                    hepatic contribution to bexarotene elimination, hepatic
                                    impairment would be expected to lead to greatly decreased
                                    clearance. Targretin<sup>&#174;</sup> capsules should be          used only with great caution in this population.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="SFB4A097C-21F2-4066-AE02-A02BBAEE1B99">
<id root="F7F87919-C25B-6ED2-6456-1C51F641D2B6" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<text><paragraph><content styleCode="italics">Thyroid axis
                                    alterations:</content> Targretin<sup>&#174;</sup> capsules
                                    induce biochemical evidence of or clinical hypothyroidism in
                                    about half of all patients treated, causing a reversible
                                    reduction in thyroid hormone (total thyroxine [total T4]) and
                                    thyroid-stimulating hormone (TSH) levels. The incidence of
                                    decreases in TSH and total T4 were about 60% and 45%,
                                    respectively, in patients with CTCL receiving an initial dose of
                                    300 mg/m<sup>2</sup>/day. Hypothyroidism was reported as an
                                    adverse event in 29% of patients. Treatment with thyroid hormone
                                    supplements should be considered in patients with laboratory
                                    evidence of hypothyroidism. In the 300 mg/m<sup>2</sup>/day
                                    initial dose group, 37% of patients were treated with thyroid
                                    hormone replacement. Baseline thyroid function tests should be
                                    obtained and patients monitored during treatment.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="S5E93EB9E-01D3-4CD8-805B-B733FFEA045E">
<id root="849EE508-139B-1D42-4077-C2ED7EBC1F3D" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<text><paragraph><content styleCode="italics">Leukopenia:</content> A
                                    total of 18% of patients with CTCL receiving an initial dose of
                                    300 mg/m<sup>2</sup>/day of Targretin<sup>&#174;</sup>
                                    capsules had reversible leukopenia in the range of 1000 to&lt;3000 WBC/mm<sup>3</sup>. Patients receiving an initial
                                    dose greater than 300 mg/m<sup>2</sup>/day of
                                        Targretin<sup>&#174;</sup> capsules had an incidence of
                                    leukopenia of 43%. No patient with CTCL treated with
                                        Targretin<sup>&#174;</sup> capsules developed leukopenia
                                    of less than 1000 WBC/mm<sup>3</sup>. The time to onset of
                                    leukopenia was generally four to eight weeks. The leukopenia
                                    observed in most patients was explained by neutropenia. In the
                                    300 mg/m<sup>2</sup>/day initial dose group, the incidence of
                                    NCI Grade 3 and Grade 4 neutropenia, respectively, was 12% and
                                    4%. The leukopenia and neutropenia experienced during
                                        Targretin<sup>&#174;</sup> capsules therapy resolved        after dose reduction or discontinuation of treatment, on average
                                    within 30 days in 93% of the patients with CTCL and 82% of
                                    patients with non-CTCL cancers. Leukopenia and neutropenia were
                                    rarely associated with severe sequelae or serious adverse
                                    events. Determination of WBC with differential should be
                                    obtained at baseline and periodically during
                                treatment.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="S8488C0B6-B545-4082-85DF-849BF50B2540">
<id root="536BC686-B8C7-2960-E504-B0557CF2E61C" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<text><paragraph><content styleCode="italics">Cataracts:</content>
                                    Posterior subcapsular cataracts were observed in preclinical
                                    toxicity studies in rats and dogs administered bexarotene daily
                                    for 6 months. In 15 of 79 patients who had serial slit lamp
                                    examinations, new cataracts or worsening of previous cataracts
                                    were found. Because of the high prevalence and rate of cataract
                                    formation in older patient populations, the relationship of
                                        Targretin<sup>&#174;</sup> capsules and cataracts cannot
                                    be determined in the absence of an appropriate control group.           Patients treated with Targretin<sup>&#174;</sup> capsules
                                    who experience visual difficulties should have an appropriate
                                    ophthalmologic evaluation.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
</section>
</component>
<component>
<section ID="SC1C4C6AA-E7D9-47D0-9197-78038A0D4F17">
<id root="0D2554A0-440F-30B4-C73C-8F8582FF2B32" />
<code code="42232-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="PRECAUTIONS" />
<title mediaType="text/x-hl7-title+xml">PRECAUTIONS</title>
<effectiveTime value="20060328" />
<component>
<section ID="SA7FADD82-5B0A-46FB-9E7B-A50045C1DAA4">
<id root="12DA6EC2-07B0-E8A2-676C-877470C4D0B3" />
<code code="42228-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="PREGNANCY" />
<text><paragraph><content styleCode="bold italics">Pregnancy:</content><content styleCode="bold">  Category X.</content> See <content styleCode="bold"><linkHtml href="#SF5DD9F0A-CDCF-4502-B2A4-7EDA828D92E9">CONTRAINDICATIONS</linkHtml></content>.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="S93C736C0-095B-42D2-BACB-C212B2B5AF4B">
<id root="E7668E10-9772-C4DD-85F6-92FF98C44AFE" />
<code code="34072-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="GENERAL PRECAUTIONS" />
<text><paragraph><content styleCode="bold italics">General:</content>  Targretin<sup>&#174;</sup> capsules should be used with
                                    caution in patients with a known hypersensitivity to retinoids.
                                    Clinical instances of cross-reactivity have not been
                                noted.</paragraph></text>
<effectiveTime value="20060328" />
<component>
<section ID="SE5338661-8FED-4E97-BA68-13DFC7D07ECC">
<id root="2C4C3C73-E5AE-FAF4-9893-E13A6A4D8C24" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<text><paragraph><content styleCode="italics">Vitamin A                                                Supplementation:</content>  In clinical studies,
                                            patients were advised to limit vitamin A intake to&#8804;15,000 IU/day. Because of the relationship of
                                            bexarotene to vitamin A, patients should be advised to
                                            limit vitamin A supplements to avoid potential additive
                                            toxic effects.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="SDB31FCDA-72A7-4058-A031-BC04ACC00CC7">
<id root="4DC465DD-FEEB-1D1A-C717-9B9D7DCA0E74" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<text><paragraph><content styleCode="italics">Patients with
                                                Diabetes Mellitus:</content>  Caution should be used
                                            when administering Targretin<sup>&#174;</sup>
                                            capsules in patients using insulin, agents enhancing
                                            insulin secretion (e.g., sulfonylureas), or
                                            insulin-sensitizers (e.g., thiazolidinedione class).
                                            Based on the mechanism of action,
                                                Targretin<sup>&#174;</sup> capsules could
                                            enhance the action of these agents, resulting in
                                            hypoglycemia. Hypoglycemia has not been associated with
                                            the use of Targretin<sup>&#174;</sup> capsules as
                                            monotherapy.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="S9A202DC5-A97B-42E0-AC55-06AD915F4A8F">
<id root="561A49EF-6FFB-E51B-0C47-2F3F6299E29C" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<text><paragraph><content styleCode="italics">Photosensitivity:</content>  Retinoids as a class have                         been associated with photosensitivity. <content styleCode="italics">In vitro</content> assays
                                            indicate that bexarotene is a potential photosensitizing
                                            agent. Mild phototoxicity manifested as sunburn and skin
                                            sensitivity to sunlight was observed in patients who
                                            were exposed to direct sunlight while receiving
                                                Targretin<sup>&#174;</sup> capsules. Patients
                                            should be advised to minimize exposure to sunlight and
                                            artificial ultraviolet light while receiving
                                                Targretin<sup>&#174;</sup> capsules.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
</section>
</component>
<component>
<section ID="S523E0640-9C6B-45EE-A284-7B403BC5AE4B">
<id root="11ECAD35-B459-A05D-7F73-A6868E726842" />
<code code="34075-2" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="LABORATORY TESTS" />
<title mediaType="text/x-hl7-title+xml">Laboratory Tests</title>
<text><paragraph>Blood lipid determinations should be performed before
                                        Targretin<sup>&#174;</sup> capsules are given. Fasting
                                    triglycerides should be normal or normalized with appropriate
                                    intervention prior to therapy. Hyperlipidemia usually occurs
                                    within the initial two to four weeks. Therefore, weekly lipid
                                    determinations are recommended during this interval.    Subsequently, in patients not hyperlipidemic, determinations can
                                    be performed less frequently (see <content styleCode="bold"><linkHtml href="#SB9C2DFAD-C326-42BC-B032-9D6D13FC5FC3">WARNINGS: Lipid abnormalities</linkHtml></content>).</paragraph><paragraph>A white blood cell count with differential should be
                                    obtained at baseline and periodically during treatment. Baseline
                                    liver function tests should be obtained and should be carefully
                                    monitored after one, two and four weeks of treatment initiation,
                                    and if stable, periodically thereafter during treatment.
                                    Baseline thyroid function tests should be obtained and then
                                    monitored during treatment as indicated (see <content styleCode="bold"><linkHtml href="#S5E93EB9E-01D3-4CD8-805B-B733FFEA045E">WARNINGS:
                                            Leukopenia</linkHtml>, <linkHtml href="#SE98A15C3-2C02-4A58-B0AC-227AB81F0F8F">Liver
                                            function test abnormalities</linkHtml></content>, and <content styleCode="bold"><linkHtml href="#SFB4A097C-21F2-4066-AE02-A02BBAEE1B99">Thyroid
                                            axis alterations</linkHtml></content>).</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="S3C0458AE-1228-460A-BB59-BCBF1EAAB56C">
<id root="025E25DE-AB9D-9C94-00A6-C92EAA652C6D" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Drug-Food Interaction</title>
<text><paragraph>In all clinical trials, patients were instructed to take
                                        Targretin<sup>&#174;</sup> capsules with or immediately
                                    following a meal. In one clinical study, plasma bexarotene AUC
                                    and C<sub>max</sub> values were substantially higher following a
                                    fat-containing meal versus those following the administration of
                                    a glucose solution. Because safety and efficacy data are based
                                    upon administration with food, it is recommended that
                                        Targretin<sup>&#174;</sup> capsules be administered with
                                    food (see <content styleCode="bold"><linkHtml href="#S8C8E17FC-02ED-4E86-B802-B372252E5FD9">CLINICAL PHARMACOLOGY: Pharmacokinetics</linkHtml></content> and <content styleCode="bold"><linkHtml href="#SCC8B9605-DEA6-4590-A5E4-846B77ACFFB7">DOSAGE AND ADMINISTRATION</linkHtml></content>).</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="SDD2BA3C4-2FCE-4972-A2A1-5E24C2A9748F">
<id root="6060CD19-AA49-17C5-7AE5-AA58714C9C90" />
<code code="34073-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="DRUG INTERACTIONS" />
<title mediaType="text/x-hl7-title+xml">Drug-Drug Interactions</title>
<text><paragraph>No formal studies to evaluate drug interactions with
                                    bexarotene have been conducted. Bexarotene oxidative metabolites
                                    appear to be formed by cytochrome P450 3A4.</paragraph><paragraph>On the basis of the metabolism of bexarotene by
                                    cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin,
                                    gemfibrozil, grapefruit juice, and other inhibitors of
                                    cytochrome P450 3A4 would be expected to lead to an increase in
                                    plasma bexarotene concentrations. Furthermore, rifampin,
                                    phenytoin, phenobarbital, and other inducers of cytochrome P450
                                    3A4 may cause a reduction in plasma bexarotene concentrations.</paragraph><paragraph>Concomitant administration of
                                    Targretin<sup>&#174;</sup> capsules and gemfibrozil resulted
                                    in substantial increases in plasma concentrations of bexarotene,
                                    probably at least partially related to cytochrome P450 3A4
                                    inhibition by gemfibrozil. Under similar conditions, bexarotene
                                    concentrations were not affected by concomitant atorvastatin
                                    administration. Concomitant administration of gemfibrozil with                              Targretin<sup>&#174;</sup> capsules is not recommended.</paragraph><paragraph>Based on interim data, concomitant administration of
                                        Targretin<sup>&#174;</sup> capsules and tamoxifen
                                    resulted in approximately a 35% decrease in plasma
                                    concentrations of tamoxifen, possibly through an induction of
                                    cytochrome P450 3A4. Based on this known interaction, bexarotene
                                    may theoretically increase the rate of metabolism and reduce
                                    plasma concentrations of other substrates metabolized by
                                    cytochrome P450 3A4, including oral or other systemic hormonal
                                    contraceptives (see <content styleCode="bold"><linkHtml href="#SB730B795-CAB5-4286-B703-9FE84B96B8E1">CLINICAL
                                        PHARMACOLOGY: Drug-Drug Interactions</linkHtml></content> and<content styleCode="bold"><linkHtml href="#SF40ACF39-8E2A-4199-B3A7-F9B6A7BAA242">CONTRAINDICATIONS: Pregnancy: Category X</linkHtml></content>). Thus,
                                    if treatment with Targretin<sup>&#174;</sup> capsules is          intended in a woman with child-bearing potential, it is strongly
                                    recommended that two reliable forms of contraception be used
                                    concurrently, one of which should be non-hormonal.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="S45052A81-EFD6-4CCB-A386-C9B6DE09ECF1">
<id root="3FA8B17A-3F4F-F1D9-6C05-45024E963311" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Renal Insufficiency</title>
<text><paragraph>No formal studies have been conducted with
                                        Targretin<sup>&#174;</sup> capsules in patients with
                                    renal insufficiency. Urinary elimination of bexarotene and its
                                    known metabolites is a minor excretory pathway for bexarotene
                                    (&lt;1% of administered dose), but because renal
                                    insufficiency can result in significant protein binding changes,
                                    and bexarotene is &gt;99% protein bound, pharmacokinetics
                                    may be altered in patients with renal insufficiency.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="SCF139D4B-B288-4E1D-8D40-DCA3EF4CCEF7">
<id root="E6F09009-7B64-D32E-A688-A56688805731" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Protein Binding</title>
<text><paragraph>Bexarotene is highly bound (&gt;99%) to plasma
                                    proteins. The plasma proteins to which bexarotene binds have not
                                    been elucidated, and the ability of bexarotene to displace drugs
                                    bound to plasma proteins and the ability of drugs to displace                          bexarotene binding have not been studied.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="S77632F4B-E04F-43AA-9C95-352A917B326F">
<id root="6526CDBC-2124-AA9E-FAD7-45ADB2504395" />
<code code="34074-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="DRUG &amp;OR LABORATORY TEST                                 INTERACTIONS" />
<title mediaType="text/x-hl7-title+xml">Drug/Laboratory Test Interactions</title>
<text><paragraph>CA125 assay values in patients with ovarian cancer may be
                                    increased by Targretin<sup>&#174;</sup> capsule
                                therapy.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="SC4F9CD89-1E19-49FB-85CC-B17F63495EFE">
<id root="A609ABA5-208D-2D20-ABEB-22325B640A7F" />
<code code="34083-6" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="CARCINOGENESIS &amp;                                 MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY" />
<title mediaType="text/x-hl7-title+xml">Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
<text><paragraph>Long-term studies in animals to assess the carcinogenic
                                    potential of bexarotene have not been conducted. Bexarotene is
                                    not mutagenic to bacteria (Ames assay) or mammalian cells (mouse
                                    lymphoma assay). Bexarotene was not clastogenic <content styleCode="italics">in vivo</content> (micronucleus test in
                                    mice). No formal fertility studies were conducted with
                                    bexarotene. Bexarotene caused testicular degeneration when oral
                                    doses of 1.5 mg/kg/day were given to dogs for 91 days (producing
                                    an AUC of approximately one fifth the AUC at the recommended
                                    human daily dose).</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="S18D7394E-1CD7-47F2-9DA7-6E0AD02D6D02">
<id root="F858E0D3-A631-909B-73F2-E72FD93C921C" />
<code code="34080-2" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="NURSING MOTHERS" />
<title mediaType="text/x-hl7-title+xml">Use in Nursing Mothers</title>
<text><paragraph>It is not known whether bexarotene is excreted in human
                                    milk. Because many drugs are excreted in human milk and because
                                    of the potential for serious adverse reactions in nursing
                                    infants from bexarotene, a decision should be made whether to
                                    discontinue nursing or to discontinue the drug, taking into
                                    account the importance of the drug to the mother.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="S20A734D5-751B-4813-923C-16B2F54AF285">
<id root="DC5A7C9D-1DE6-4897-1650-E71D4A51C654" />
<code code="34081-0" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="PEDIATRIC USE" />
<title mediaType="text/x-hl7-title+xml">Pediatric Use</title>
<text><paragraph>Safety and effectiveness in pediatric patients have not
                                    been established.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="SECC3BA83-006D-487C-8AD5-BC8EA76E7A23">
<id root="138731E7-6950-BB67-AF29-994D16AFBA53" />
<code code="34082-8" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="GERIATRIC USE" />
<title mediaType="text/x-hl7-title+xml">Geriatric Use</title>
<text><paragraph>Of the total patients with CTCL in clinical studies of
                                        Targretin<sup>&#174;</sup> capsules, 64% were 60 years
                                    or older, while 33% were 70 years or older. No overall
                                    differences in safety were observed between patients 70 years or
                                    older and younger patients, but greater sensitivity of some
                                    older individuals to Targretin<sup>&#174;</sup> capsules
                                    cannot be ruled out. Responses to Targretin<sup>&#174;</sup>
                                    capsules were observed across all age group decades, without
                                    preference for any individual age group decade.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
</section>
</component>
<component>
<section ID="SFB884CA1-3066-4454-9BE4-72DDADBB2E8F">
<id root="370F0B50-7C63-C504-1835-2B0B9ED06423" />
<code code="34084-4" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="ADVERSE REACTIONS" />
<title mediaType="text/x-hl7-title+xml">ADVERSE REACTIONS</title>
<text><paragraph>The safety of Targretin<sup>&#174;</sup> capsules has been
                            evaluated in clinical studies of 152 patients with CTCL who received
                                Targretin<sup>&#174;</sup> capsules for up to 97 weeks and in
                            352 patients in other studies. The mean duration of therapy for the 152
                            patients with CTCL was 166 days. The most common adverse events reported
                            with an incidence of at least 10% in patients with CTCL treated at an
                            initial dose of 300 mg/m<sup>2</sup>/day of
                            Targretin<sup>&#174;</sup> capsules are shown in Table 1. The events
                            at least possibly related to treatment are lipid abnormalities (elevated
                            triglycerides, elevated total and LDL cholesterol and decreased HDL
                            cholesterol), hypothyroidism, headache, asthenia, rash, leukopenia,
                            anemia, nausea, infection, peripheral edema, abdominal pain, and dry                 skin. Most adverse events occurred at a higher incidence in patients
                            treated at starting doses of greater than 300 mg/m<sup>2</sup>/day (see<linkHtml href="#Tf6eb19ad-e737-412a-a0d7-43fe08586e7f">Table
                            1</linkHtml>).</paragraph><paragraph>Adverse events leading to dose reduction or study drug
                            discontinuation in at least two patients were hyperlipemia,
                            neutropenia/leukopenia, diarrhea, fatigue/lethargy, hypothyroidism,
                            headache, liver function test abnormalities, rash, pancreatitis, nausea,
                            anemia, allergic reaction, muscle spasm, pneumonia, and confusion.</paragraph><paragraph>The moderately severe (NCI Grade 3) and severe (NCI Grade 4)
                            adverse events reported in two or more patients with CTCL treated at an
                            initial dose of 300 mg/m<sup>2</sup>/day of
                            Targretin<sup>&#174;</sup> capsules (see <linkHtml href="#T137c4b37-4dd0-4801-8f93-9c9158f29f8e">Table 2</linkHtml>)
                            were hypertriglyceridemia, pruritus, headache, peripheral edema,
                            leukopenia, rash, and hypercholesteremia. Most of these moderately
                            severe or severe adverse events occurred at a higher rate in patients
                            treated at starting doses of greater than 300 mg/m<sup>2</sup>/day than
                            in patients treated at a starting dose of 300 mg/m<sup>2</sup>/day.</paragraph><paragraph>As shown in Table 3, in patients with CTCL receiving an initial
                            dose of 300 mg/m<sup>2</sup>/day, the incidence of NCI Grade 3 or 4
                            elevations in triglycerides and total cholesterol was 28% and 25%,
                            respectively. In contrast, in patients with CTCL receiving greater than    300 mg/m<sup>2</sup>/day, the incidence of NCI Grade 3 or 4 elevated
                            triglycerides and total cholesterol was 45% and 45%, respectively. Other
                            Grade 3 and 4 laboratory abnormalities are shown in Table 3.</paragraph><paragraph>In addition to the 152 patients enrolled in the two CTCL studies,
                            352 patients received Targretin<sup>&#174;</sup> capsules as
                            monotherapy for various advanced malignancies at doses from 5
                            mg/m<sup>2</sup>/day to 1000 mg/m<sup>2</sup>/day. The common adverse
                            events (incidence greater than 10%) were similar to those seen in
                            patients with CTCL.</paragraph><paragraph>In the 504 patients (CTCL and non-CTCL) who received
                                Targretin<sup>&#174;</sup> capsules as monotherapy, drug-related
                            serious adverse events that were fatal, in one patient each, were acute
                            pancreatitis, subdural hematoma, and liver failure. </paragraph><paragraph>In the patients with CTCL receiving an initial dose of 300
                                mg/m<sup>2</sup>/day of Targretin<sup>&#174;</sup> capsules,
                            adverse events reported at an incidence of less than 10% and not
                            included in Tables 1-3 or discussed in other parts of labeling and
                            possibly related to treatment were as follows:</paragraph><paragraph><content styleCode="bold">Body as a Whole:</content> chills,
                            cellulitis, chest pain, sepsis, and monilia.</paragraph><paragraph><content styleCode="bold">Cardiovascular:</content> hemorrhage,
                            hypertension, angina pectoris, right heart failure, syncope, and
                            tachycardia.</paragraph><paragraph><content styleCode="bold">Digestive:</content> constipation, dry                     mouth, flatulence, colitis, dyspepsia, cheilitis, gastroenteritis,
                            gingivitis, liver failure, and melena.</paragraph><paragraph><content styleCode="bold">Hemic and Lymphatic:</content>
                            eosinophilia, thrombocythemia, coagulation time increased,
                            lymphocytosis, and thrombocytopenia.</paragraph><paragraph><content styleCode="bold">Metabolic and Nutritional:</content>
                            LDH increased, creatinine increased, hypoproteinemia, hyperglycemia,
                            weight decreased, weight increased, and amylase increased.</paragraph><paragraph><content styleCode="bold">Musculoskeletal:</content> arthralgia,
                            myalgia, bone pain, myasthenia, and arthrosis.</paragraph><paragraph><content styleCode="bold">Nervous:</content> depression,
                            agitation, ataxia, cerebrovascular accident, confusion, dizziness,
                            hyperesthesia, hypesthesia, and neuropathy.</paragraph><paragraph><content styleCode="bold">Respiratory:</content> pharyngitis,
                            rhinitis, dyspnea, pleural effusion, bronchitis, cough increased, lung
                            edema, hemoptysis, and hypoxia.</paragraph><paragraph><content styleCode="bold">Skin and Appendages:</content> skin
                            ulcer, acne, alopecia, skin nodule, macular papular rash, pustular rash,
                            serous drainage, and vesicular bullous rash.</paragraph><paragraph><content styleCode="bold">Special Senses:</content> dry eyes,
                            conjunctivitis, ear pain, blepharitis, corneal lesion, keratitis, otitis
                            externa, and visual field defect.</paragraph><paragraph><content styleCode="bold">Urogenital:</content> albuminuria,
                            hematuria, urinary incontinence, urinary tract infection, urinary
                            urgency, dysuria, kidney function abnormal, and breast pain.</paragraph><table ID="Tf6eb19ad-e737-412a-a0d7-43fe08586e7f"><caption>Table 1.&#160;&#160;&#160;&#160;Adverse Events
                                with Incidence &#8805;10% in CTCL Trials</caption>
<colgroup>
<col align="left" />
<col align="center" />
<col align="center" />
</colgroup>
<thead>
<tr><th /><th colspan="3">Initial Assigned Dose
                                        Group<br />(mg/m<sup>2</sup>/day)</th></tr>
<tr><th /><th>300</th><th /><th>&gt;300</th></tr>
<tr><th>Body
                                        System<br />&#160;&#160;&#160;&#160;Adverse
                                            Event<sup>1,2</sup></th><th>N=84<br />N (%)</th><th /><th>N=53<br />N (%)</th></tr>
</thead>
<tfoot>
<tr><td colspan="4"><paragraph><caption><sup>1</sup></caption> Preferred English term coded according to
                                            Ligand-modified COSTART 5 Dictionary.</paragraph><paragraph><caption><sup>2</sup></caption> Patients are counted at most once in each AE
                                            category.</paragraph></td></tr>
</tfoot>
<tbody>
<tr><td><paragraph>METABOLIC AND NUTRITIONAL DISORDERS</paragraph></td><td /><td /><td /></tr>
<tr><td><paragraph>&#160;&#160;&#160;&#160;Hyperlipemia<br />&#160;&#160;&#160;&#160;Hypercholesteremia<br />&#160;&#160;&#160;&#160;Lactic
                                            dehydrogenase increased</paragraph></td><td><paragraph>66 (78.6)<br />27 (32.1)<br />6 (7.1)</paragraph></td><td /><td><paragraph>42 (79.2)<br />33 (62.3)<br />7 (13.2)</paragraph></td></tr>
<tr><td><paragraph>BODY AS A
                                            WHOLE<br />&#160;&#160;&#160;&#160;Headache<br />&#160;&#160;&#160;&#160;Asthenia<br />&#160;&#160;&#160;&#160;Infection<br />&#160;&#160;&#160;&#160;Abdominal     pain<br />&#160;&#160;&#160;&#160;Chills<br />&#160;&#160;&#160;&#160;Fever<br />&#160;&#160;&#160;&#160;Flu
                                            syndrome<br />&#160;&#160;&#160;&#160;Back
                                            pain<br />&#160;&#160;&#160;&#160;Infection
                                            bacterial</paragraph></td><td><paragraph><br />25 (29.8)<br />17 (20.2)<br />11 (13.1)<br />9
                                            (10.7)<br />8 (9.5)<br />4 (4.8)<br />3 (3.6)<br />2
                                            (2.4)<br />1 (1.2)</paragraph></td><td /><td><paragraph><br />22 (41.5)<br />24 (45.3)<br />12 (22.6)<br />2
                                            (3.8)<br />7 (13.2)<br />9 (17.0)<br />7 (13.2)<br />6
                                            (11.3)<br />7 (13.2)</paragraph></td></tr>
<tr><td><paragraph>ENDOCRINE<br />&#160;&#160;&#160;&#160;Hypothyroidism</paragraph></td><td><paragraph><br />24 (28.6)</paragraph></td><td /><td><paragraph><br />28 (52.8)</paragraph></td></tr>
<tr><td><paragraph>SKIN AND
                                            APPENDAGES<br />&#160;&#160;&#160;&#160;Rash<br />&#160;&#160;&#160;&#160;Dry
                                            skin<br />&#160;&#160;&#160;&#160;Exfoliative
                                            dermatitis<br />&#160;&#160;&#160;&#160;Alopecia</paragraph></td><td><paragraph><br />14 (16.7)<br />9 (10.7)<br />8 (9.5)<br />3
                                            (3.6)</paragraph></td><td /><td><paragraph><br />12 (22.6)<br />5 (9.4)<br />15 (28.3)<br />6
                                            (11.3)</paragraph></td></tr>
<tr><td><paragraph>HEMIC AND LYMPHATIC SYSTEM</paragraph></td><td /><td /><td /></tr>
<tr><td><paragraph>&#160;&#160;&#160;&#160;Leukopenia<br />&#160;&#160;&#160;&#160;Anemia<br />&#160;&#160;&#160;&#160;Hypochromic
                                            anemia</paragraph></td><td><paragraph>14 (16.7)<br />5 (6.0)<br />3 (3.6)</paragraph></td><td /><td><paragraph>25 (47.2)<br />13 (24.5)<br />7 (13.2)</paragraph></td></tr>
<tr><td><paragraph>DIGESTIVE
                                            SYSTEM<br />&#160;&#160;&#160;&#160;Nausea<br />&#160;&#160;&#160;&#160;Diarrhea<br />&#160;&#160;&#160;&#160;Vomiting<br />&#160;&#160;&#160;&#160;Anorexia</paragraph></td><td><paragraph><br />13 (15.5)<br />6 (7.1)<br />3 (3.6)<br />2
                                            (2.4)</paragraph></td><td /><td><paragraph><br />4 (7.5)<br />22 (41.5)<br />7 (13.2)<br />12
                                            (22.6)</paragraph></td></tr>
<tr><td><paragraph>CARDIOVASCULAR
                                            SYSTEM<br />&#160;&#160;&#160;&#160;Peripheral
                                            edema</paragraph></td><td><paragraph><br />11 (13.1)</paragraph></td><td /><td><paragraph><br />6 (11.3)</paragraph></td></tr>
<tr><td><paragraph>NERVOUS
                                            SYSTEM<br />&#160;&#160;&#160;&#160;Insomnia</paragraph></td><td><paragraph><br />4 (4.8)</paragraph></td><td /><td><paragraph><br />6 (11.3)</paragraph></td></tr>
</tbody>
</table><table ID="T137c4b37-4dd0-4801-8f93-9c9158f29f8e"><caption>Table 2.&#160;&#160;&#160;&#160;Incidence of
                                Moderately Severe and Severe Adverse Events Reported in at Least Two
                                Patients (CTCL Trials)</caption>
<colgroup>
<col align="left" />
<col align="center" />
<col align="center" />
<col align="center" />
<col align="center" />
<col align="center" />
</colgroup>
<thead>
<tr><th /><th colspan="5">Initial Assigned Dose Group
                                        (mg/m<sup>2</sup>/day)</th></tr>
<tr><th /><th colspan="2">300 (N=84)</th><th /><th colspan="2">&gt;300 (N=53)</th></tr>
<tr><th /><th>Mod Sev</th><th>Severe</th><th /><th>Mod Sev</th><th>Severe</th></tr>
<tr><th>Body
                                        System<br />&#160;&#160;&#160;&#160;Adverse
                                            Event<sup>1,2</sup></th><th><br />N (%)</th><th><br />N (%)</th><th /><th><br />N (%)</th><th><br />N (%)</th></tr>
</thead>
<tfoot>
<tr><td colspan="6"><paragraph><caption><sup>1</sup></caption> Preferred English term coded according to
                                            Ligand-modified COSTART 5 Dictionary.</paragraph><paragraph><caption><sup>2</sup></caption> Patients are counted at most once in each AE
                                            category. Patients are classified by the highest
                                            severity within each row.</paragraph></td></tr>
</tfoot>
<tbody>
<tr><td><paragraph>BODY AS A
                                            WHOLE<br />&#160;&#160;&#160;&#160;Asthenia<br />&#160;&#160;&#160;&#160;Headache<br />&#160;&#160;&#160;&#160;Infection            bacterial</paragraph></td><td><paragraph><br />1 (1.2)<br />3 (3.6)<br />1 (1.2)</paragraph></td><td><paragraph><br />0 (0.0)<br />0 (0.0)<br />0 (0.0)</paragraph></td><td /><td><paragraph><br />11 (20.8)<br />5 (9.4)<br />0
                                        (0.0)</paragraph></td><td><paragraph><br />0 (0.0)<br />1 (1.9)<br />2 (3.8)</paragraph></td></tr>
<tr><td><paragraph>CARDIOVASCULAR
                                            SYS.&#160;<br />&#160;&#160;&#160;&#160;Peripheral
                                            edema</paragraph></td><td><paragraph><br />2 (2.4)</paragraph></td><td><paragraph><br />1 (1.2)</paragraph></td><td /><td><paragraph><br />0 (0.0)</paragraph></td><td><paragraph><br />0 (0.0)</paragraph></td></tr>
<tr><td><paragraph>DIGESTIVE
                                            SYSTEM<br />&#160;&#160;&#160;&#160;Anorexia<br />&#160;&#160;&#160;&#160;Diarrhea<br />&#160;&#160;&#160;&#160;Pancreatitis<br />&#160;&#160;&#160;&#160;Vomiting</paragraph></td><td><paragraph><br />0 (0.0)<br />1 (1.2)<br />1 (1.2)<br />0
                                        (0.0)</paragraph></td><td><paragraph><br />0 (0.0)<br />1 (1.2)<br />0 (0.0)<br />0
                                        (0.0)</paragraph></td><td /><td><paragraph><br />3 (5.7)<br />2 (3.8)<br />3 (5.7)<br />2
                                        (3.8)</paragraph></td><td><paragraph><br />0 (0.0)<br />1 (1.9)<br />0 (0.0)<br />0
                                        (0.0)</paragraph></td></tr>
<tr><td><paragraph>ENDOCRINE<br />&#160;&#160;&#160;&#160;Hypothyroidism</paragraph></td><td><paragraph><br />1 (1.2)</paragraph></td><td><paragraph><br />1 (1.2)</paragraph></td><td /><td><paragraph><br />2 (3.8)</paragraph></td><td><paragraph><br />0 (0.0)</paragraph></td></tr>
<tr><td><paragraph>HEM. &amp; LYMPH.
                                            SYS.<br />&#160;&#160;&#160;&#160;Leukopenia</paragraph></td><td><paragraph><br />3 (3.6)</paragraph></td><td><paragraph><br />0 (0.0)</paragraph></td><td /><td><paragraph><br />6 (11.3)</paragraph></td><td><paragraph><br />1 (1.9)</paragraph></td></tr>
<tr><td><paragraph>META. AND NUTR.
                                            DIS.<br />&#160;&#160;&#160;&#160;Bilirubinemia<br />&#160;&#160;&#160;&#160;Hypercholesteremia<br />&#160;&#160;&#160;&#160;Hyperlipemia<br />&#160;&#160;&#160;&#160;SGOT/AST
                                            increased<br />&#160;&#160;&#160;&#160;SGPT/ALT
                                            increased</paragraph></td><td><paragraph><br />0 (0.0)<br />2 (2.4)<br />16 (19.0)<br />0
                                            (0.0)<br />0 (0.0)</paragraph></td><td><paragraph><br />1 (1.2)<br />0 (0.0)<br />6 (7.1)<br />0
                                            (0.0)<br />0 (0.0)</paragraph></td><td /><td><paragraph><br />2 (3.8)<br />5 (9.4)<br />17 (32.1)<br />2
                                            (3.8)<br />2 (3.8)</paragraph></td><td><paragraph><br />0 (0.0)<br />0 (0.0)<br />5 (9.4)<br />0
                                            (0.0)<br />0 (0.0)</paragraph></td></tr>
<tr><td><paragraph>RESPIRATORY
                                            SYSTEM<br />&#160;&#160;&#160;&#160;Pneumonia</paragraph></td><td><paragraph><br />0 (0.0)</paragraph></td><td><paragraph><br />0 (0.0)</paragraph></td><td /><td><paragraph><br />2 (3.8)</paragraph></td><td><paragraph><br />2 (3.8)</paragraph></td></tr>
<tr><td><paragraph>SKIN AND
                                            APPENDAGES<br />&#160;&#160;&#160;&#160;Exfoliative
                                            dermatitis<br />&#160;&#160;&#160;&#160;Rash</paragraph></td><td><paragraph><br />0 (0.0)<br />1 (1.2)</paragraph></td><td><paragraph><br />1 (1.2)<br />2 (2.4)</paragraph></td><td /><td><paragraph><br />3 (5.7)<br />1 (1.9)</paragraph></td><td><paragraph><br />1 (1.9)<br />0 (0.0)</paragraph></td></tr>
</tbody>
</table><table ID="T5aa49ebc-efda-4349-9cde-0ccf15754278"><caption>Table
                                3.&#160;&#160;&#160;&#160;Treatment-Emergent
                                Abnormal Laboratory Values in CTCL Trials</caption>
<colgroup>
<col align="left" />
<col align="center" />
<col align="center" />
<col align="center" />
<col align="center" />
<col align="center" />
</colgroup>
<thead>
<tr><th /><th colspan="5">Initial Assigned Dose
                                    (mg/m<sup>2</sup>/day)</th></tr>
<tr><th /><th colspan="2">300</th><th /><th colspan="2">&gt;300</th></tr>
<tr><th /><th colspan="2">N=83<sup>1</sup></th><th /><th colspan="2">N=53<sup>1</sup></th></tr>
<tr><th><br />Analyte</th><th>Grade 3<sup>2</sup><br />(%)</th><th>Grade 4<sup>2</sup><br />(%)</th><th /><th>Grade 3<br />(%)</th><th>Grade 4<br />(%)</th></tr>
</thead>
<tfoot>
<tr><td colspan="6"><paragraph><caption><sup>1</sup></caption> Number of patients with at least one analyte
                                            value post-baseline.</paragraph><paragraph><caption><sup>2</sup></caption>Adapted from NCI Common Toxicity Criteria,
                                            Grade 3 and 4, Version 2.0. Patients are considered to
                                            have had a Grade 3 or 4 value if either of the following
                                            occurred: a) Value becomes Grade 3 or 4 during the
                                            study; b) Value is abnormal at baseline and worsens to
                                            Grade 3 or 4 on study, including all values beyond study
                                            drug discontinuation, as defined in data handling
                                            conventions.</paragraph><paragraph><caption><sup>3</sup></caption>The denominator used to calculate the
                                            incidence rates for fasting Total Cholesterol and
                                            Triglycerides were N=75 for the 300 mg/m<sup>2</sup>/day
                                            initial dose group and N=44 for the &gt;300
                                                mg/m<sup>2</sup>/day initial dose group.</paragraph></td></tr>
</tfoot>
<tbody>
<tr><td><paragraph><br />Triglycerides<sup>3</sup><br />Total
                                                Cholesterol<sup>3</sup><br /><br />Alkaline
                                            Phosphatase<br />Hyperglycemia<br />Hypocalcemia<br />Hyponatremia<br />SGPT/ALT<br />Hyperkalemia<br />Hypernatremia<br />SGOT/AST<br />Total
                                            Bilirubin<br /><br />ANC<br />ALC<br />WBC<br />Hemoglobin</paragraph></td><td><paragraph><br />21.3<br />18.7<br /><br />1.2<br />1.2<br />1.2<br />1.2<br />1.2<br />0.0<br />0.0<br />0.0<br />0.0<br /><br />12.0<br />7.2<br />3.6<br />0.0</paragraph></td><td><paragraph><br />6.7<br />6.7<br /><br />0.0<br />0.0<br />0.0<br />0.0<br />0.0<br />0.0<br />1.2<br />0.0<br />0.0<br /><br />3.6<br />0.0<br />0.0<br />0.0</paragraph></td><td /><td><paragraph><br />31.8<br />15.9<br /><br />0.0<br />5.7<br />0.0<br />9.4<br />1.9<br />1.9<br />0.0<br />1.9<br />0.0<br /><br />18.9<br />15.1<br />11.3<br />1.9</paragraph></td><td><paragraph><br />13.6<br />29.5<br /><br />1.9<br />0.0<br />0.0<br />0.0<br />1.9<br />0.0<br />0.0<br />1.9<br />1.9<br /><br />7.5<br />0.0<br />0.0<br />0.0</paragraph></td></tr>
</tbody>
</table></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="S3C2F8E47-44BF-4A2E-B07F-2B089FE1F097">
<id root="724E852E-9931-DEEA-12F7-C403F85D284E" />
<code code="34088-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="OVERDOSAGE" />
<title mediaType="text/x-hl7-title+xml">OVERDOSAGE</title>
<text><paragraph>Doses up to 1000 mg/m<sup>2</sup>/day of
                            Targretin<sup>&#174;</sup> capsules have been administered in
                            short-term studies in patients with advanced cancer without acute toxic
                            effects. Single doses of 1500 mg/kg and 720 mg/kg were tolerated without
                            significant toxicity in rats and dogs, respectively. These doses are                approximately 30 and 50 times, respectively, the recommended human dose
                            on a mg/m<sup>2</sup> basis.</paragraph><paragraph>No clinical experience with an overdose of
                                Targretin<sup>&#174;</sup> capsules has been reported. Anyoverdose with Targretin<sup>&#174;</sup> capsules should be treated
                            with supportive care for the signs and symptoms exhibited by the
                            patient.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="SCC8B9605-DEA6-4590-A5E4-846B77ACFFB7">
<id root="E6EE4F4C-520C-7C65-6057-DFFF1CC8E03F" />
<code code="34068-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="DOSAGE &amp; ADMINISTRATION" />
<title mediaType="text/x-hl7-title+xml">DOSAGE AND ADMINISTRATION</title>
<text><paragraph>The recommended initial dose of Targretin<sup>&#174;</sup>
                            capsules is 300 mg/m<sup>2</sup>/day. (See <linkHtml href="#TEA99C952-A894-4C86-A0C5-CEAD5BC576D6">Table 4</linkHtml>.)
                                Targretin<sup>&#174;</sup> capsules should be taken as a single
                            oral daily dose with a meal. See <content styleCode="bold"><linkHtml href="#SF40ACF39-8E2A-4199-B3A7-F9B6A7BAA242">CONTRAINDICATIONS:
                                Pregnancy: Category X</linkHtml></content> section for precautions to prevent
                            pregnancy and birth defects in women of child-bearing potential.</paragraph><table ID="TEA99C952-A894-4C86-A0C5-CEAD5BC576D6"><caption>Table
                                    4.&#160;&#160;&#160;&#160;Targretin<sup>&#174;</sup>
                                Capsule Initial Dose Calculation According to Body Surface Area</caption>
<colgroup>
<col align="center" />
<col align="center" />
<col align="center" />
</colgroup>
<thead>
<tr><th colspan="2">Initial Dose Level (300 mg/m<sup>2</sup>/day)</th><th rowspan="2">Number of 75
                                        mg<br />Targretin<sup>&#174;</sup> Capsules</th></tr>
<tr><th>Body Surface Area<br />(m<sup>2</sup>)</th><th>Total Daily Dose<br />(mg/day)</th></tr>
</thead>
<tbody>
<tr><td><paragraph>0.88 - 1.12</paragraph></td><td><paragraph>300</paragraph></td><td><paragraph>4</paragraph></td></tr>
<tr><td><paragraph>1.13 - 1.37</paragraph></td><td><paragraph>375</paragraph></td><td><paragraph>5</paragraph></td></tr>
<tr><td><paragraph>1.38 - 1.62</paragraph></td><td><paragraph>450</paragraph></td><td><paragraph>6</paragraph></td></tr>
<tr><td><paragraph>1.63 - 1.87</paragraph></td><td><paragraph>525</paragraph></td><td><paragraph>7</paragraph></td></tr>
<tr><td><paragraph>1.88 - 2.12</paragraph></td><td><paragraph>600</paragraph></td><td><paragraph>8</paragraph></td></tr>
<tr><td><paragraph>2.13 - 2.37</paragraph></td><td><paragraph>675</paragraph></td><td><paragraph>9</paragraph></td></tr>
<tr><td><paragraph>2.38 - 2.62</paragraph></td><td><paragraph>750</paragraph></td><td><paragraph>10</paragraph></td></tr>
</tbody>
</table><paragraph>Dose Modification Guidelines: The 300 mg/m<sup>2</sup>/day dose
                            level of Targretin<sup>&#174;</sup> capsules may be adjusted to 200
                                mg/m<sup>2</sup>/day then to 100 mg/m<sup>2</sup>/day, or
                            temporarily suspended, if necessitated by toxicity. When toxicity is
                            controlled, doses may be carefully readjusted upward. If there is no
                            tumor response after eight weeks of treatment and if the initial dose of
                            300 mg/m<sup>2</sup>/day is well tolerated, the dose may be escalated to
                            400 mg/m<sup>2</sup>/day with careful monitoring. </paragraph><paragraph>Duration of Therapy: In clinical trials in CTCL,
                                Targretin<sup>&#174;</sup> capsules were administered for up to
                            97 weeks.</paragraph><paragraph>Targretin<sup>&#174;</sup> capsules should be continued as
                            long as the patient is deriving benefit.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="S82289FF8-83E2-44F9-8020-158960AB9DB1">
<id root="340C758D-5D42-D85B-467A-98337711B143" />
<code code="34069-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="HOW SUPPLIED" />
<title mediaType="text/x-hl7-title+xml">HOW SUPPLIED</title>
<text><paragraph>Targretin<sup>&#174;</sup> capsules are supplied as 75 mg
                            off-white, oblong soft gelatin capsules, imprinted with&#8220;Targretin&#8221;, in high density polyethylene bottles
                            with child-resistant closures.</paragraph><paragraph>Bottles of 100
                            capsules........................................................................
                            NDC 64365-502-01</paragraph><paragraph>Store at 2<sup>&#176;</sup>-25<sup>&#176;</sup>C
                                (36<sup>&#176;</sup>-77<sup>&#176;</sup>F). Avoid exposing
                            to high temperatures and humidity after the bottle is opened. Protect
                            from light.</paragraph><paragraph>Manufactured for:<br />Ligand Pharmaceuticals
                            Incorporated<br />San Diego, CA 92121</paragraph><paragraph>Medical Information Telephone Number: (800) 964-5836</paragraph><paragraph>Manufactured by:<br />Cardinal
                            Health<br />St. Petersburg, FL 33716</paragraph><paragraph>&#8220;Ligand&#8221;, the Ligand logo and
                                Targretin<sup>&#174;</sup> are registered trademarks of Ligand
                            Pharmaceuticals, Inc.</paragraph><paragraph>U.S. Patent Nos. 5,466,861, 5,780,676, and 5,962,731</paragraph><paragraph>Ligand Part
                            #3000207&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(Rev.
                            0403)<br />Anderson Part #5422101-03</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
</structuredBody>
</component>
</document>
